Amicus Therapeutics (NASDAQ:FOLD) Stock Price Up 3.2%

Amicus Therapeutics, Inc. (NASDAQ:FOLD) shares were up 3.2% during mid-day trading on Tuesday . The stock traded as high as $11.98 and last traded at $11.98. Approximately 227,974 shares traded hands during mid-day trading, a decline of 92% from the average daily volume of 2,814,438 shares. The stock had previously closed at $11.61.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Bank of America decreased their price objective on Amicus Therapeutics from $14.00 to $13.00 and set a “buy” rating for the company in a report on Friday, May 10th. Needham & Company LLC reiterated a “hold” rating on shares of Amicus Therapeutics in a research report on Friday, August 9th. Guggenheim raised shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating and set a $13.00 target price on the stock in a report on Tuesday, May 14th. JPMorgan Chase & Co. dropped their price objective on Amicus Therapeutics from $17.00 to $16.00 and set an “overweight” rating for the company in a research report on Friday, August 16th. Finally, Wells Fargo & Company initiated coverage on Amicus Therapeutics in a research note on Thursday, May 30th. They issued an “overweight” rating and a $18.00 price target for the company. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $17.14.

Amicus Therapeutics Price Performance

The company has a current ratio of 2.75, a quick ratio of 2.26 and a debt-to-equity ratio of 2.93. The company has a market capitalization of $3.46 billion, a P/E ratio of -23.22 and a beta of 0.71. The business’s fifty day moving average price is $10.75 and its 200-day moving average price is $10.90.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.05) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.05). The company had revenue of $126.67 million for the quarter, compared to analysts’ expectations of $121.21 million. Amicus Therapeutics had a negative net margin of 26.23% and a negative return on equity of 41.47%. Amicus Therapeutics’s quarterly revenue was up 34.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.15) earnings per share. As a group, sell-side analysts predict that Amicus Therapeutics, Inc. will post -0.1 earnings per share for the current fiscal year.

Insider Activity

In other news, CEO Bradley L. Campbell sold 6,100 shares of the business’s stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $10.00, for a total value of $61,000.00. Following the sale, the chief executive officer now directly owns 886,654 shares in the company, valued at approximately $8,866,540. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. In related news, CEO Bradley L. Campbell sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, August 1st. The shares were sold at an average price of $10.34, for a total transaction of $77,550.00. Following the completion of the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $9,168,002.36. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Bradley L. Campbell sold 6,100 shares of the company’s stock in a transaction that occurred on Friday, July 5th. The shares were sold at an average price of $10.00, for a total transaction of $61,000.00. Following the transaction, the chief executive officer now owns 886,654 shares in the company, valued at approximately $8,866,540. The disclosure for this sale can be found here. Insiders own 2.20% of the company’s stock.

Institutional Trading of Amicus Therapeutics

Several large investors have recently made changes to their positions in the business. Comerica Bank lifted its holdings in Amicus Therapeutics by 0.8% during the fourth quarter. Comerica Bank now owns 103,418 shares of the biopharmaceutical company’s stock valued at $1,468,000 after purchasing an additional 774 shares in the last quarter. Van ECK Associates Corp boosted its stake in shares of Amicus Therapeutics by 23.1% in the fourth quarter. Van ECK Associates Corp now owns 4,657 shares of the biopharmaceutical company’s stock valued at $66,000 after purchasing an additional 873 shares during the period. Xponance Inc. lifted its stake in Amicus Therapeutics by 5.3% in the second quarter. Xponance Inc. now owns 18,555 shares of the biopharmaceutical company’s stock worth $184,000 after acquiring an additional 936 shares during the last quarter. Franklin Resources Inc. lifted its position in shares of Amicus Therapeutics by 2.3% during the 4th quarter. Franklin Resources Inc. now owns 54,943 shares of the biopharmaceutical company’s stock worth $780,000 after buying an additional 1,258 shares during the last quarter. Finally, American International Group Inc. lifted its position in shares of Amicus Therapeutics by 0.9% during the 4th quarter. American International Group Inc. now owns 141,249 shares of the biopharmaceutical company’s stock worth $2,004,000 after buying an additional 1,298 shares during the last quarter.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.